|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lei Z, Tan IB, Das K, Deng N, Zouridis H,
Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al: Identification
of molecular subtypes of gastric cancer with different responses to
PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology.
145:554–565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board: The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar :
|
|
5
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and So-called intestinal-type
carcinoma. An attempt at a Histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakamura K, Sugano H and Takagi K:
Carcinoma of the stomach in incipient phase: Its histogenesis and
histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI
|
|
7
|
Korfer J, Lordick F and Hacker UT:
Molecular targets for gastric cancer treatment and future
perspectives from a clinical and translational point of view.
Cancers (Basel). 13:52162021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis GD, Figari I, Fendly B, Wong WL,
Carter P, Gorman C and Shepard HM: Differential responses of human
tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer
Immunol Immunother. 37:255–263. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JB, Rhim JS, Park SC, Kimm SW and
Kraus MH: Amplification, overexpression, and rearrangement of the
erbB-2 protooncogene in primary human stomach carcinomas. Cancer
Res. 49:6605–6609. 1989.PubMed/NCBI
|
|
10
|
Maeda K, Chung YS, Ogawa Y, Ko T, Ogawa M,
Onoda N, Kato Y, Arimoto Y, Nitta A and Sowa M: Expression of
vascular endothelial cell growth factor as a predictor of
recurrence in gastric carcinoma. Gan To Kagaku Ryoho. 22:699–701.
1995.In Japanese. PubMed/NCBI
|
|
11
|
Maeda K, Chung YS, Ogawa Y, Takatsuka S,
Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular
endothelial growth factor expression in gastric carcinoma. Cancer.
77:858–863. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guan WL, He Y and Xu RH: Gastric cancer
treatment: Recent progress and future perspectives. J Hematol
Oncol. 16:572023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alsina M, Arrazubi V, Diez M and Tabernero
J: Current developments in gastric cancer: From molecular profiling
to treatment strategy. Nat Rev Gastroenterol Hepatol. 20:155–170.
2023. View Article : Google Scholar
|
|
14
|
Shah MA, Khanin R, Tang L, Janjigian YY,
Klimstra DS, Gerdes H and Kelsen DP: Molecular classification of
gastric cancer: A new paradigm. Clin Cancer Res. 17:2693–2701.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan IB, Ivanova T, Lim KH, Ong CW, Deng N,
Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of
gastric cancer, based on gene expression pattern, predict survival
and respond differently to chemotherapy. Gastroenterology.
141:476–485. e1–e11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Cheng WY, Shi H, Huang S, Chen H,
Liu D, Xu W, Yu J and Wang J: Classifying gastric cancer using
FLORA reveals clinically relevant molecular subtypes and highlights
LINC01614 as a biomarker for patient prognosis. Oncogene.
40:2898–2909. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li L and Wang X: Identification of gastric
cancer subtypes based on pathway clustering. NPJ Precis Oncol.
5:462021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu Z, Qin J, Dong C, Yang J, Yang M, Tian
J and Zhong X: Identification of four gastric cancer subtypes based
on genetic analysis of cholesterogenic and glycolytic pathways.
Bioengineered. 12:4780–4793. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li L and Ma J: Molecular characterization
of metabolic subtypes of gastric cancer based on metabolism-related
lncRNA. Sci Rep. 11:214912021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu D, Feng M, Shen H, Shen X, Hu J, Liu J,
Yang Y, Li Y, Yang M, Wang W, et al: Prediction of two molecular
subtypes of gastric cancer based on immune signature. Front Genet.
12:7934942021. View Article : Google Scholar
|
|
22
|
Ning ZK, Hu CG, Liu J, Tian HK, Yu ZL,
Zhou HN, Li H and Zong Z: The hypoxic landscape stratifies gastric
cancer into 3 subtypes with distinct M6a methylation and tumor
microenvironment infiltration characteristics. Front Immunol.
13:8600412022. View Article : Google Scholar
|
|
23
|
Zhu Y, Zhao Y, Cao Z, Chen Z and Pan W:
Identification of three immune subtypes characterized by distinct
tumor immune microenvironment and therapeutic response in stomach
adenocarcinoma. Gene. 818:1461772022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He F, Ding H, Zhou Y, Wang Y, Xie J, Yang
S and Zhu Y: Depiction of Aging-Based molecular phenotypes with
diverse clinical prognosis and immunological features in gastric
cancer. Front Med (Lausanne). 8:7927402021. View Article : Google Scholar
|
|
25
|
Li B, Zhang F, Niu Q, Liu J, Yu Y, Wang P,
Zhang S, Zhang H and Wang Z: A molecular classification of gastric
cancer associated with distinct clinical outcomes and validated by
an XGBoost-based prediction model. Mol Ther Nucleic Acids.
31:224–240. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen T, Zhao L, Chen J, Jin G, Huang Q,
Zhu M, Dai R, Yuan Z, Chen J, Tang M, et al: Identification of
three metabolic subtypes in gastric cancer and the construction of
a metabolic pathway-based risk model that predicts the overall
survival of GC patients. Front Genet. 14:10948382023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tao G, Wen X, Wang X and Zhou Q: Bulk and
single-cell transcriptome profiling reveal the metabolic
heterogeneity in gastric cancer. Sci Rep. 13:87872023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu X, Wang Z, Wang Q, Chen K, Han Q, Bai
S, Du J and Chen W: Molecular classification reveals the diverse
genetic and prognostic features of gastric cancer: A multi-omics
consensus ensemble clustering. Biomed Pharmacother. 144:1122222021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Loh M, Liem N, Vaithilingam A, Lim PL,
Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, et al: DNA
methylation subgroups and the CpG island methylator phenotype in
gastric cancer: A comprehensive profiling approach. BMC
Gastroenterol. 14:552014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Bai W and Zhang X: Identifying
heterogeneous subtypes of gastric cancer and subtype-specific
subpaths of microRNA-target pathways. Mol Med Rep. 17:3583–3590.
2018.
|
|
32
|
Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE,
Park KC, Lee SH, Park JL, Park YY, Lee HS, et al: Clinical and
genomic landscape of gastric cancer with a mesenchymal phenotype.
Nat Commun. 9:17772018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mun DG, Bhin J, Kim S, Kim H, Jung JH,
Jung Y, Jang YE, Park JM, Kim H, Jung Y, et al: Proteogenomic
characterization of human Early-Onset gastric cancer. Cancer Cell.
35:111–124.e10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng
J, Yuan J, Chen R, Li Y, Ge Z, et al: A proteomic landscape of
diffuse-type gastric cancer. Nat Commun. 9:10122018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tong M, Yu C, Shi J, Huang W, Ge S, Liu M,
Song L, Zhan D, Xia X, Liu W, et al: Phosphoproteomics enables
molecular subtyping and nomination of kinase candidates for
individual patients of Diffuse-Type gastric cancer. iScience.
22:44–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Ding Y, Chen Y, Jiang J, Chen Y,
Lu J, Kong M, Mo F, Huang Y, Zhao W, et al: A novel genomic
classification system of gastric cancer via integrating
multidimensional genomic characteristics. Gastric Cancer.
24:1227–1241. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li S, Yuan L, Xu ZY, Xu JL, Chen GP, Guan
X, Pan GZ, Hu C, Dong J, Du YA, et al: Integrative proteomic
characterization of adenocarcinoma of esophagogastric junction. Nat
Commun. 14:7782023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi W, Wang Y, Xu C, Li Y, Ge S, Bai B,
Zhang K, Wang Y, Zheng N, Wang J, et al: Multilevel proteomic
analyses reveal molecular diversity between diffuse-type and
intestinal-type gastric cancer. Nat Commun. 14:8352023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Kunzke T, Prade VM, Shen J, Buck
A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, et al:
Spatial metabolomics identifies distinct Tumor-Specific subtypes in
gastric cancer patients. Clin Cancer Res. 28:2865–2877. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cao J, Gong J, Li X, Hu Z, Xu Y, Shi H, Li
D, Liu G, Jie Y, Hu B and Chong Y: Unsupervised hierarchical
clustering identifies immune gene subtypes in gastric cancer. Front
Pharmacol. 12:6924542021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang J, Ge J, Wang Y, Xiong F, Guo J,
Jiang X, Zhang L, Deng X, Gong Z, Zhang S, et al: EBV miRNAs BART11
and BART17-3p promote immune escape through the enhancer-mediated
transcription of PD-L1. Nat Commun. 13:8662022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang J, Liu Z, Zeng B, Hu G and Gan R:
Epstein-Barr virus-associated gastric cancer: A distinct subtype.
Cancer Lett. 495:191–199. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hirata T, Yamamoto H, Taniguchi H,
Horiuchi S, Oki M, Adachi Y, Imai K and Shinomura Y:
Characterization of the immune escape phenotype of human gastric
cancers with and without high-frequency microsatellite instability.
J Pathol. 211:516–523. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Corso G, Velho S, Paredes J, Pedrazzani C,
Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M,
et al: Oncogenic mutations in gastric cancer with microsatellite
instability. Eur J Cancer. 47:443–451. 2011. View Article : Google Scholar
|
|
45
|
Mulkidjan RS, Saitova ES, Preobrazhenskaya
EV, Asadulaeva KA, Bubnov MG, Otradnova EA, Terina DM, Shulga SS,
Martynenko DE, Semina MV, et al: ALK, ROS1, RET and NTRK1-3 Gene
fusions in colorectal and Non-colorectal microsatellite-unstable
cancers. Int J Mol Sci. 24:136102023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chida K, Kawazoe A, Kawazu M, Suzuki T,
Nakamura Y, Nakatsura T, Kuwata T, Ueno T, Kuboki Y, Kotani D, et
al: A low tumor mutational burden and PTEN mutations are predictors
of a negative response to PD-1 blockade in MSI-H/dMMR
gastrointestinal tumors. Clin Cancer Res. 27:3714–3724. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Polom K, Das K, Marrelli D, Roviello G,
Pascale V, Voglino C, Rho H, Tan P and Roviello F: KRAS mutation in
gastric cancer and prognostication associated with microsatellite
instability status. Pathol Oncol Res. 25:333–340. 2019. View Article : Google Scholar
|
|
48
|
Hwang HS, Kim D and Choi J: Distinct
mutational profile and immune microenvironment in
microsatellite-unstable and POLE-mutated tumors. J Immunother
Cancer. 9:e0027972021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Giampieri R, Maccaroni E, Mandolesi A, Del
Prete M, Andrikou K, Faloppi L, Bittoni A, Bianconi M, Scarpelli M,
Bracci R, et al: Mismatch repair deficiency may affect clinical
outcome through immune response activation in metastatic gastric
cancer patients receiving first-line chemotherapy. Gastric Cancer.
20:156–163. 2017. View Article : Google Scholar
|
|
50
|
Kim KJ, Lee KS, Cho HJ, Kim YH, Yang HK,
Kim WH and Kang GH: Prognostic implications of tumor-infiltrating
FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in
microsatellite-unstable gastric cancers. Hum Pathol. 45:285–293.
2014. View Article : Google Scholar
|
|
51
|
Yoshida T, Ogura G, Tanabe M, Hayashi T,
Ohbayashi C, Azuma M, Kunisaki C, Akazawa Y, Ozawa S, Matsumoto S,
et al: Clinicopathological features of PD-L1 protein expression,
EBV positivity, and MSI status in patients with advanced gastric
and esophagogastric junction adenocarcinoma in Japan. Cancer Biol
Ther. 23:191–200. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan
J, Zhong X, Li X, Qian H, Wang X, et al: PD-L1 and gastric cancer
prognosis: A systematic review and meta-analysis. PLoS One.
12:e01826922017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dislich B, Mertz KD, Gloor B and Langer R:
Interspatial distribution of tumor and immune cells in correlation
with PD-L1 in molecular subtypes of gastric cancers. Cancers
(Basel). 14:17362022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
He CY, Qiu MZ, Yang XH, Zhou DL, Ma JJ,
Long YK, Ye ZL, Xu BH, Zhao Q, Jin Y, et al: Classification of
gastric cancer by EBV status combined with molecular profiling
predicts patient prognosis. Clin Transl Med. 10:353–362. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hawkins RD, Hon GC and Ren B:
Next-generation genomics: An integrative approach. Nat Rev Genet.
11:476–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bornschein J, Wernisch L, Secrier M,
Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S,
Bower L, et al: Transcriptomic profiling reveals three molecular
phenotypes of adenocarcinoma at the gastroesophageal junction. Int
J Cancer. 145:3389–3401. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Werner H, Meisel-Sharon S and Bruchim I:
Oncogenic fusion proteins adopt the insulin-like growth factor
signaling pathway. Mol Cancer. 17:282018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tauriello DVF, Palomo-Ponce S, Stork D,
Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M,
Ibiza S, Cañellas A, Hernando-Momblona X, et al: TGFβ drives immune
evasion in genetically reconstituted colon cancer metastasis.
Nature. 554:538–543. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFbeta attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xie F, Zhou X, Li H, Su P, Liu S, Li R,
Zou J, Wei X, Pan C, Zhang Z, et al: USP8 promotes cancer
progression and extracellular vesicle-mediated CD8+ T cell
exhaustion by deubiquitinating the TGF-β receptor TβRII. EMBO J.
41:e1087912022. View Article : Google Scholar
|
|
66
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Goldenring JR and Nomura S:
Differentiation of the gastric mucosa III. Animal models of oxyntic
atrophy and metaplasia. Am J Physiol Gastrointest Liver Physiol.
291:G999–G1004. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ma Y, Zhu J, Chen S, Li T, Ma J, Guo S, Hu
J, Yue T, Zhang J, Wang P, et al: Activated gastric
cancer-associated fibroblasts contribute to the malignant phenotype
and 5-FU resistance via paracrine action in gastric cancer. Cancer
Cell Int. 18:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Howe LR, Subbaramaiah K, Hudis CA and
Dannenberg AJ: Molecular pathways: Adipose inflammation as a
mediator of obesity-associated cancer. Clin Cancer Res.
19:6074–6083. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Manousopoulou A, Hayden A, Mellone M,
Garay-Baquero DJ, White CH, Noble F, Lopez M, Thomas GJ, Underwood
TJ and Garbis SD: Quantitative proteomic profiling of primary
cancer-associated fibroblasts in oesophageal adenocarcinoma. Br J
Cancer. 118:1200–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Calcagno DQ, Leal MF, Assumpcao PP, Smith
MA and Burbano RR: MYC and gastric adenocarcinoma carcinogenesis.
World J Gastroenterol. 14:5962–5968. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Park KU, Lee HE, Park DJ, Jung EJ, Song J,
Kim HH, Choe G, Kim WH and Lee HS: MYC quantitation in cell-free
plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem
Lab Med. 47:530–536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhao L, Liu Y, Zhang S, Wei L, Cheng H and
Wang J and Wang J: Impacts and mechanisms of metabolic
reprogramming of tumor microenvironment for immunotherapy in
gastric cancer. Cell Death Dis. 13:3782022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Davoli T, Uno H, Wooten EC and Elledge SJ:
Tumor aneuploidy correlates with markers of immune evasion and with
reduced response to immunotherapy. Science. 355:eaaf83992017.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gandara DR, Paul SM, Kowanetz M,
Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G,
Malboeuf C, et al: Blood-based tumor mutational burden as a
predictor of clinical benefit in non-small-cell lung cancer
patients treated with atezolizumab. Nat Med. 24:1441–1448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Mandal R, Samstein RM, Lee KW, Havel JJ,
Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, et al:
Genetic diversity of tumors with mismatch repair deficiency
influences anti-PD-1 immunotherapy response. Science. 364:485–491.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cai L, Li L, Ren D, Song X, Mao B, Han B
and Zhang H: Prognostic impact of gene copy number instability and
tumor mutation burden in patients with resectable gastric cancer.
Cancer Commun (Lond). 40:63–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang D, Wang N, Li X, Chen X, Shen B, Zhu
D, Zhu L, Xu Y, Yu Y and Shu Y: Tumor mutation burden as a
biomarker in resected gastric cancer via its association with
immune infiltration and hypoxia. Gastric Cancer. 24:823–834. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Mani DR, Krug K, Zhang B, Satpathy S,
Clauser KR, Ding L, Ellis M, Gillette MA and Carr SA: Cancer
proteogenomics: Current impact and future prospects. Nat Rev
Cancer. 22:298–313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mertins P, Mani DR, Ruggles KV, Gillette
MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, et al:
Proteogenomics connects somatic mutations to signalling in breast
cancer. Nature. 534:55–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pozniak Y, Balint-Lahat N, Rudolph JD,
Lindskog C, Katzir R, Avivi C, Pontén F, Ruppin E, Barshack I and
Geiger T: System-wide clinical proteomics of breast cancer reveals
global remodeling of tissue homeostasis. Cell Syst. 2:172–184.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Vasaikar S, Huang C, Wang X, Petyuk VA,
Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, et al:
Proteogenomic analysis of human colon cancer reveals new
therapeutic opportunities. Cell. 177:1035–1049.e19. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jayavelu AK, Wolf S, Buettner F, Alexe G,
Häupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S,
et al: The proteogenomic subtypes of acute myeloid leukemia. Cancer
Cell. 40:301–317.e12. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tong Y, Sun M, Chen L, Wang Y, Li Y, Li L,
Zhang X, Cai Y, Qie J, Pang Y, et al: Proteogenomic insights into
the biology and treatment of pancreatic ductal adenocarcinoma. J
Hematol Oncol. 15:1682022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhang C, Chong X, Jiang F, Gao J, Chen Y,
Jia K, Fan M, Liu X, An J, Li J, et al: Plasma extracellular
vesicle derived protein profile predicting and monitoring
immunotherapeutic outcomes of gastric cancer. J Extracell Vesicles.
11:e122092022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Melero I, Berman DM, Aznar MA, Korman AJ,
Perez Gracia JL and Haanen J: Evolving synergistic combinations of
targeted immunotherapies to combat cancer. Nat Rev Cancer.
15:457–472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu M, Wang X, Wang L, Ma X, Gong Z, Zhang
S and Li Y: Targeting the IDO1 pathway in cancer: From bench to
bedside. J Hematol Oncol. 11:1002018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Barnes TA and Amir E: HYPE or HOPE: The
prognostic value of infiltrating immune cells in cancer. Br J
Cancer. 117:451–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Kim RS, Song N, Gavin PG, Salgado R,
Bandos H, Kos Z, Floris G, Eynden GGGMVD, Badve S, Demaria S, et
al: Stromal tumor-infiltrating lymphocytes in NRG Oncology/NSABP
B-31 adjuvant trial for Early-Stage HER2-Positive breast cancer. J
Natl Cancer Inst. 111:867–871. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Paijens ST, Vledder A, de Bruyn M and
Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 18:842–859. 2021. View Article : Google Scholar :
|
|
92
|
Liu D, Heij LR, Czigany Z, Dahl E, Lang
SA, Ulmer TF, Luedde T, Neumann UP and Bednarsch J: The role of
tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin
Cancer Res. 41:1272022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lascarez-Lagunas LI, Nadarajan S,
Martinez-Garcia M, Quinn JN, Todisco E, Thakkar T, Berson E, Eaford
D, Crawley O, Montoya A, et al: ATM/ATR kinases link the
synaptonemal complex and DNA double-strand break repair pathway
choice. Curr Biol. 32:4719–4726.e4. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Goel S, DeCristo MJ, Watt AC, BrinJones H,
Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, et
al: CDK4/6 inhibition triggers anti-tumour immunity. Nature.
548:471–475. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Pritzl CJ, Luera D, Knudson KM, Quaney MJ,
Calcutt MJ, Daniels MA and Teixeiro E: IKK2/NFkB signaling controls
lung resident CD8+ T cell memory during influenza
infection. Nat Commun. 14:43312023. View Article : Google Scholar
|
|
96
|
Chang CP, Su YC, Lee PH and Lei HY:
Targeting NFKB by autophagy to polarize hepatoma-associated
macrophage differentiation. Autophagy. 9:619–621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zinatizadeh MR, Schock B, Chalbatani GM,
Zarandi PK, Jalali SA and Miri SR: The Nuclear Factor Kappa B
(NF-kB) signaling in cancer development and immune diseases. Genes
Dis. 8:287–297. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chevallay M, Bollschweiler E, Chandramohan
SM, Schmidt T, Koch O, Demanzoni G, Mönig S and Allum W: Cancer of
the gastroesophageal junction: A diagnosis, classification, and
management review. Ann N Y Acad Sci. 1434:132–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vial M, Grande L and Pera M: Epidemiology
of adenocarcinoma of the esophagus, gastric cardia, and upper
gastric third. Recent Results Cancer Res. 182:1–17. 2010.PubMed/NCBI
|
|
100
|
Gao Y, Xin L, Lin H, Yao B, Zhang T, Zhou
AJ, Huang S, Wang JH, Feng YD, Yao SH, et al: Machine
learning-based automated sponge cytology for screening of
oesophageal squamous cell carcinoma and adenocarcinoma of the
oesophagogastric junction: A nationwide, multicohort, prospective
study. Lancet Gastroenterol Hepatol. 8:432–445. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Menghi F, Orzan FN, Eoli M, Farinotti M,
Maderna E, Pisati F, Bianchessi D, Valletta L, Lodrini S, Galli G,
et al: DNA microarray analysis identifies CKS2 and LEPR as
potential markers of meningioma recurrence. Oncologist.
16:1440–1450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Qiu H, Lin X, Tang W, Liu C, Chen Y, Ding
H, Kang M and Chen S: Investigation of TCF7L2, LEP and LEPR
polymorphisms with esophageal squamous cell carcinomas. Oncotarget.
8:109107–109119. 2017. View Article : Google Scholar
|
|
103
|
Liu CR, Li Q, Hou C, Li H, Shuai P, Zhao
M, Zhong XR, Xu ZP and Li JY: Changes in body mass index, leptin,
and leptin receptor polymorphisms and breast cancer risk. DNA Cell
Biol. 37:182–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Yu H, Pan R, Qi Y, Zheng Z, Li J, Li H,
Ying J, Xu M and Duan S: LEPR hypomethylation is significantly
associated with gastric cancer in males. Exp Mol Pathol.
116:1044932020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wei Y, Wang X, Zhang Z, Zhao C, Chang Y,
Bian Z and Zhao X: Impact of NR5A2 and RYR2 3'UTR polymorphisms on
the risk of breast cancer in a Chinese Han population. Breast
Cancer Res Treat. 183:1–8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH,
Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, et al: Expression of
DBC1 and SIRT1 is associated with poor prognosis of gastric
carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bae JS, Park SH, Jamiyandorj U, Kim KM,
Noh SJ, Kim JR, Park HJ, Kwon KS, Jung SH, Park HS, et al:
CK2alpha/CSNK2A1 Phosphorylates SIRT6 and is involved in the
progression of breast carcinoma and predicts shorter survival of
diagnosed patients. Am J Pathol. 186:3297–3315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G,
Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, et al: FBXO44
promotes DNA replication-coupled repetitive element silencing in
cancer cells. Cell. 184:352–369.e23. 2021. View Article : Google Scholar :
|
|
109
|
Mattei AL, Bailly N and Meissner A: DNA
methylation: A historical perspective. Trends Genet. 38:676–707.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Papanicolau-Sengos A and Aldape K: DNA
methylation profiling: An emerging paradigm for cancer diagnosis.
Annu Rev Pathol. 17:295–321. 2022. View Article : Google Scholar
|
|
111
|
Johnson CH, Ivanisevic J and Siuzdak G:
Metabolomics: Beyond biomarkers and towards mechanisms. Nat Rev Mol
Cell Biol. 17:451–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Peng L, Chen L, Wan J, Liu W, Lou S and
Shen Z: Single-cell transcriptomic landscape of immunometabolism
reveals intervention candidates of ascorbate and aldarate
metabolism, fatty-acid degradation and PUFA metabolism of T-cell
subsets in healthy controls, psoriasis and psoriatic arthritis.
Front Immunol. 14:11798772023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Kwon J and Bakhoum SF: The cytosolic
DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov. 10:26–39.
2020. View Article : Google Scholar :
|
|
114
|
Vandereyken K, Sifrim A, Thienpont B and
Voet T: Methods and applications for single-cell and spatial
multi-omics. Nat Rev Genet. 24:494–515. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu
E, Wei W, Li G, Cheng X, Xue L, et al: Integrated multi-omics
profiling yields a clinically relevant molecular classification for
esophageal squamous cell carcinoma. Cancer Cell. 41:181–195.e9.
2023. View Article : Google Scholar
|
|
116
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar :
|
|
117
|
Xu Y, She Y, Li Y, Li H, Jia Z, Jiang G,
Liang L and Duan L: Multi-omics analysis at epigenomics and
transcriptomics levels reveals prognostic subtypes of lung squamous
cell carcinoma. Biomed Pharmacother. 125:1098592020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Feng D, Gao P, Henley N, Dubuissez M, Chen
N, Laurin LP, Royal V, Pichette V and Gerarduzzi C: SMOC2 promotes
an epithelial-mesenchymal transition and a pro-metastatic phenotype
in epithelial cells of renal cell carcinoma origin. Cell Death Dis.
13:6392022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Mullen J, Kato S, Sicklick JK and Kurzrock
R: Targeting ARID1A mutations in cancer. Cancer Treat Rev.
100:1022872021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hansford S, Kaurah P, Li-Chang H, Woo M,
Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K,
Zogopoulos G, et al: Hereditary diffuse gastric cancer syndrome:
CDH1 mutations and beyond. JAMA Oncol. 1:23–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Cochran BJ, Ong KL, Manandhar B and Rye
KA: APOA1: A protein with multiple therapeutic functions. Curr
Atheroscler Rep. 23:112021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Chia NY and Tan P: Molecular
classification of gastric cancer. Ann Oncol. 27:763–769. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Nakayama I, Qi C, Chen Y, Nakamura Y, Shen
L and Shitara K: Claudin 18.2 as a novel therapeutic target. Nat
Rev Clin Oncol. 21:354–369. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Shitara K, Lordick F, Bang YJ, Enzinger P,
Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al:
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive,
HER2-negative, untreated, locally advanced unresectable or
metastatic gastric or gastro-oesophageal junction adenocarcinoma
(SPOTLIGHT): A multicentre, randomised, double-blind, phase 3
trial. Lancet. 401:1655–1668. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Shah MA, Shitara K, Ajani JA, Bang YJ,
Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J,
Huang J, et al: Zolbetuximab plus CAPOX in CLDN18.2-positive
gastric or gastroesophageal junction adenocarcinoma: The
randomized, phase 3 GLOW trial. Nat Med. 29:2133–2141. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Sahin U, Tureci O, Manikhas G, Lordick F,
Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B,
et al: FAST: A randomised phase II study of zolbetuximab (IMAB362)
plus EOX versus EOX alone for first-line treatment of advanced
CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol. 32:609–619. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Klempner SJ, Lee KW, Shitara K, Metges JP,
Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, et al:
ILUSTRO: Phase II multicohort trial of zolbetuximab in patients
with advanced or metastatic claudin 18.2-Positive gastric or
gastroesophageal junction adenocarcinoma. Clin Cancer Res.
29:3882–3891. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Joshi SS and Badgwell BD: Current
treatment and recent progress in gastric cancer. CA Cancer J Clin.
71:264–279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant
capecitabine and oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled
trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
De Vita F, Giuliani F, Galizia G, Belli C,
Aurilio G, Santabarbara G, Ciardiello F, Catalano G and Orditura M:
Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann
Oncol. 18(Suppl 6): vi120–vi123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluorouracil have low gene expression levels of dihydropyrimidine
dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
|
|
132
|
White C, Scott RJ, Paul C, Ziolkowski A,
Mossman D, Fox SB, Michael M and Ackland S: Dihydropyrimidine
dehydrogenase deficiency and implementation of upfront DPYD
genotyping. Clin Pharmacol Ther. 112:791–802. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zhao F, Li E, Shen G, Dong Q, Ren D, Wang
M, Zhao Y, Liu Z, Ma J, Xie Q, et al: Correlation between mismatch
repair and survival of patients with gastric cancer after
5-FU-based adjuvant chemotherapy. J Gastroenterol. 58:622–632.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hoppe MM, Sundar R, Tan DSP and
Jeyasekharan AD: Biomarkers for homologous recombination deficiency
in cancer. J Natl Cancer Inst. 110:704–713. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Golan T, O'Kane GM, Denroche RE,
Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH,
Stossel C, et al: Genomic features and classification of homologous
recombination deficient pancreatic ductal adenocarcinoma.
Gastroenterology. 160:2119–2132.e9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Rodler E, Sharma P, Barlow WE, Gralow JR,
Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA,
Huynh TT, et al: Cisplatin with veliparib or placebo in metastatic
triple-negative breast cancer and BRCA mutation-associated breast
cancer (S1416): A randomised, double-blind, placebo-controlled,
phase 2 trial. Lancet Oncol. 24:162–174. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Telli ML, Timms KM, Reid J, Hennessy B,
Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, et
al: Homologous recombination deficiency (HRD) score predicts
response to platinum-containing neoadjuvant chemotherapy in
patients with Triple-Negative breast cancer. Clin Cancer Res.
22:3764–3773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhu Y, Hu Y, Tang C, Guan X and Zhang W:
Platinum-based systematic therapy in triple-negative breast cancer.
Biochim Biophys Acta Rev Cancer. 1877:1886782022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Ott K, Vogelsang H, Mueller J, Becker K,
Müller M, Fink U, Siewert JR, Höfler H and Keller G: Chromosomal
instability rather than p53 mutation is associated with response to
neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin
Cancer Res. 9:2307–2315. 2003.PubMed/NCBI
|
|
140
|
Kumar S, Nandi A, Singh S, Regulapati R,
Li N, Tobias JW, Siebel CW, Blanco MA, Klein-Szanto AJ, Lengner C,
et al: Dll1(+) quiescent tumor stem cells drive chemoresistance in
breast cancer through NF-kappaB survival pathway. Nat Commun.
12:4322021. View Article : Google Scholar
|
|
141
|
Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW and
Liu RS: STAT3/NF-κB-regulated lentiviral TK/GCV suicide gene
therapy for cisplatin-resistant triple-negative breast cancer.
Theranostics. 7:647–663. 2017. View Article : Google Scholar :
|
|
142
|
Liu W, Wang Z, Liu S, Zhang X, Cao X and
Jiang M: RNF138 inhibits late inflammatory gene transcription
through degradation of SMARCC1 of the SWI/SNF complex. Cell Rep.
42:1120972023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Mittal P and Roberts CWM: The SWI/SNF
complex in cancer-biology, biomarkers and therapy. Nat Rev Clin
Oncol. 17:435–448. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Botta GP, Kato S, Patel H, Fanta P, Lee S,
Okamura R and Kurzrock R: SWI/SNF complex alterations as a
biomarker of immunotherapy efficacy in pancreatic cancer. JCI
Insight. 6:e1504532021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Gluckstein MI, Dintner S, Arndt TT,
Vlasenko D, Schenkirsch G, Agaimy A, Müller G, Märkl B and Grosser
B: Comprehensive immunohistochemical study of the SWI/SNF complex
expression status in gastric cancer reveals an adverse prognosis of
SWI/SNF deficiency in genomically stable gastric carcinomas.
Cancers (Basel). 13:38942021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Iwagami Y, Eguchi H, Nagano H, Akita H,
Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, et
al: miR-320c regulates gemcitabine-resistance in pancreatic cancer
via SMARCC1. Br J Cancer. 109:502–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Deng J, Bai X, Feng X, Ni J, Beretov J,
Graham P and Li Y: Inhibition of PI3K/Akt/mTOR signaling pathway
alleviates ovarian cancer chemoresistance through reversing
epithelial-mesenchymal transition and decreasing cancer stem cell
marker expression. BMC Cancer. 19:6182019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Peng Y, Wang Y, Zhou C, Mei W and Zeng C:
PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we
making headway? Front Oncol. 12:8191282022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yu M, Chen J, Xu Z Yang B, He Q, Luo P,
Yan H and Yang X: Development and safety of PI3K inhibitors in
cancer. Arch Toxicol. 97:635–650. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar
|
|
152
|
Pereira MA, Dias AR, Ramos MFKP, Cardili
L, Moraes RDR, Zilberstein B, Nahas SC, Mello ES and Ribeiro U Jr:
Gastric cancer with microsatellite instability displays increased
thymidylate synthase expression. J Surg Oncol. 126:116–124. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Puliga E, Corso S, Pietrantonio F and
Giordano S: Microsatellite instability in gastric cancer: Between
lights and shadows. Cancer Treat Rev. 95:1021752021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Liu X, Choi MG, Kim K, Kim KM, Kim ST,
Park SH, Cristescu R, Peter S and Lee J: High PD-L1 expression in
gastric cancer (GC) patients and correlation with molecular
features. Pathol Res Pract. 216:1528812020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kim TS, da Silva E, Coit DG and Tang LH:
Intratumoral immune response to gastric cancer varies by molecular
and histologic subtype. Am J Surg Pathol. 43:851–860. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Bai Y, Xie T, Wang Z, Tong S, Zhao X, Zhao
F, Cai J, Wei X, Peng Z and Shen L: Efficacy and predictive
biomarkers of immunotherapy in Epstein-Barr virus-associated
gastric cancer. J Immunother Cancer. 10:e0040802022. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Wang Z, Wang X, Xu Y, Li J, Zhang X, Peng
Z, Hu Y, Zhao X, Dong K, Zhang B, et al: Mutations of PI3K-AKT-mTOR
pathway as predictors for immune cell infiltration and
immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC
Med. 20:1332022. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Panda A, Mehnert JM, Hirshfield KM,
Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN,
Poplin E, et al: Immune activation and benefit from avelumab in
EBV-positive gastric cancer. J Natl Cancer Inst. 110:316–320. 2018.
View Article : Google Scholar
|
|
159
|
Saito M and Kono K: Landscape of
EBV-positive gastric cancer. Gastric Cancer. 24:983–989. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Cheong JE and Sun L: Targeting the
IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy-challenges and
opportunities. Trends Pharmacol Sci. 39:307–325. 2018. View Article : Google Scholar
|
|
161
|
Niu F, Yu Y, Li Z, Ren Y, Li Z, Ye Q, Liu
P, Ji C, Qian L and Xiong Y: Arginase: An emerging and promising
therapeutic target for cancer treatment. Biomed Pharmacother.
149:1128402022. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ichikawa H, Nagahashi M, Shimada Y, Hanyu
T, Ishikawa T, Kameyama H, Kobayashi T, Sakata J, Yabusaki H,
Nakagawa S, et al: Actionable gene-based classification toward
precision medicine in gastric cancer. Genome Med. 9:932017.
View Article : Google Scholar : PubMed/NCBI
|
